US · Healthcare · Biotechnology
EPS came in at -1.20 against a street estimate of -0.31 — a miss of 287.1%.
Analysts rate Enlivex Therapeutics Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $1,280.00.
| Fund | Stake |
|---|---|
| ARK Investment Management LLC | 0.80% |
| Springbok Capital Management, LLC | 0.11% |
| Bank of America Corp | 0.06% |
| Two Sigma Investments LLC | 0.06% |
| Susquehanna International Group, LLP | 0.05% |
| Renaissance Technologies Corp | 0.04% |
| Geode Capital Management, LLC | 0.04% |
| JPMorgan Chase & Co | 0.04% |
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 16 effective Oct 27, 2026 | 2026-10-27 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Enlivex Therapeutics Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.